Buoyed by the market share held by biosimilars of the short-acting neutropenia drug Neupogen, Coherus hopes its Udenyca price, contracts and services will give its biosimilar a significant share of the market for the longer-acting Neulasta.
Looking ahead to the launch of its Neulasta (pegfilgrastim) biosimilar, Coherus BioSciences Inc. executives are encouraged by the US market for Amgen Inc.'s short-acting neutropenia drug Neupogen (filgrastim), where sales are split equally between the brand and the two biosimilars on the market – better penetration than most biosimilars in the US.
Coherus is preparing for a Jan. 3 launch of Udenyca (pegfilgrastim-cbqv), its biosimilar of Amgen's long-acting neutropenia drug Neulasta, and...
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
